TICKERNERD
Menu
HROWHROWHealthcare · Drug Manufacturers - Specialty & Generic

HROW Stock Forecast: Harrow, Inc. Price Predictions for 2026-2027

Last close, 21 Sept 2026
$34
+2.52% on the day

The 9 Wall Street analysts covering Harrow, Inc. hold a median 12-month price target of $60 — +76.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 45 of 100 as at 19 Sept 2026 — in the lower half.

Market cap
$1.2B
Ticker Nerd rank
45 / 100
Median analyst target
$60
Analysts covering
9
Revenue$70.7M+10.9% y/y
Operating income−$11.0M
Net income−$17.3M
Free cash flow−$10.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.5%
1M
−17.2%
YTD
−30.8%
1Y
−23.5%
From 52W high
−38.1%
From 52W low
+16.8%
$29
$55
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

HROW stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Harrow, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
45 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
93
Value
76
Accruals
71
Momentum
44
Size
42
Growth
41
Volatility
38
Revisions
32
Issuance
16

Quality (93): The business earns solid, repeatable profits on what it owns.

Issuance (16): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

HROW stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HROW, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$30$40$50$60$70$80$90Oct 25Jan 26Apr 26Jul 26HROWHigh $88Median $60Low $45

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
9 Buy0 Hold0 Sell
Low $45Median $60High $88

The green dot is the last close — the median target sits +76.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
9 Sept 2026Leerink PartnersInitiatesOutperform$45
11 Aug 2026BTIGReiteratesBuy—
11 Aug 2026BTIGReiteratesBuy$63
21 July 2026BTIGReiteratesBuy$63
21 July 2026BTIGReiteratesBuy—
13 May 2026Cantor FitzgeraldMaintainsOverweight—
13 May 2026Cantor FitzgeraldMaintainsOverweight$91 → $88
12 May 2026BTIGReiteratesBuy—
12 May 2026BTIGReiteratesBuy$63
17 Apr 2026BTIGReiteratesBuy—
7 Apr 2026B. Riley SecuritiesReiteratesBuy—
19 Mar 2026HC Wainwright & Co.ReiteratesBuy—
18 Mar 2026BTIGReiteratesBuy—
4 Mar 2026Cantor FitzgeraldMaintainsOverweight—
4 Mar 2026HC Wainwright & Co.MaintainsBuy—
12 Nov 2025HC Wainwright & Co.MaintainsBuy—
12 Nov 2025Ladenburg ThalmannMaintainsBuy—
1 Oct 2025B. Riley SecuritiesReiteratesBuy—
29 Sept 2025BTIGReiteratesBuy—
29 Sept 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HROW appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

HROW vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 21 Sept 2026, Harrow, Inc. returned −23.5% against +15.7% for the S&P 500, dividends included.

HROW vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Oct 25Jan 26Apr 26Jul 26HROWS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

HROW analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+1.5%
Analysts raising
0
Analysts cutting
2
Fundamentals

Harrow, Inc. (HROW) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−236.3×

Cheaper than 99% of US stocks

Price / sales
4.5×

Cheaper than 27% of US stocks

Price / book
81.5×

Cheaper than 2% of US stocks

EV / EBITDA
82.1×

Cheaper than 3% of US stocks

Growth & margins
Revenue growth (YoY)
10.9%

Higher than 55% of US stocks

Earnings growth (YoY)
10.9%

Higher than 49% of US stocks

Gross margin
71.3%

Higher than 84% of US stocks

Operating margin
−15.6%

Higher than 22% of US stocks

Net margin
−13.5%

Higher than 18% of US stocks

Returns & dividend
Return on equity
−116.1%

Higher than 12% of US stocks

Return on assets
−0.5%

Higher than 42% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Harrow, Inc. (HROW) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Harrow, Inc. has a market value of $1.2B and an enterprise value of $1.5B.

  • Revenue in the twelve months to 30 June 2026: $275.6M. The latest quarter grew 10.9% year on year.

  • Net income over the same four quarters: −$37.2M, a −13.5% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.00.

  • Free cash flow in the twelve months to 30 June 2026: −$13.1M.

  • Shares outstanding: 37.5M.

  • Trailing P/E: −236.3×; forward P/E: 11.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Harrow, Inc. employs 373 people — $739K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Sept 2026

Data provided by Twelve Data

Peers

HROW vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
HROWHarrow, Inc.$1.2B
45
PAHCPhibro Animal Health Corp.$1.4B
92
AMPHAmphastar Pharmaceuticals, Inc.$1.0B
85
XERSXeris Biopharma Holdings, Inc.$1.5B
83
PCRXPacira Biosciences, Inc.$999.7M
99
ETONEton Pharmaceuticals, Inc.$1.6B
99
ANIPANI Pharmaceuticals, Inc.$1.7B
93

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Harrow, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest HROW news & analysis

Harrow to Participate in Three Investor Conferences in September

GlobeNewsWire · 1 Sept 2026neutral

Harrow announced that its management will participate in three investor conferences in September in New York, NY, including the 2026 Cantor Global Healthcare Conference, scheduled for September 9, 2026, featuring a fireside chat and one-on-one investor meetings.

Why it matters — Investors following Harrow may be interested in the company's participation in these conferences as an opportunity for management to engage directly with the investment community.

Harrow's Iheezo Cuts Eye-Injection Discomfort by More Than Half

Benzinga · 21 Aug 2026positive

Harrow Inc. reported results from a prospective, randomized, contralateral-eye clinical study showing that its Iheezo product reduced eye-injection discomfort by more than half. The announcement was shared on Thursday and highlights the ophthalmic disease management company's clinical data.

Why it matters — A HROW watcher would care because positive clinical results for Iheezo could support the product's positioning and commercial prospects.

Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections

GlobeNewsWire · 20 Aug 2026positive

Harrow announced patient-reported data for IHEEZO following intravitreal injections, indicating approximately 58% less overall discomfort in the IHEEZO-treated eye, with the largest differences in the immediate post-injection period when discomfort is highest.

Why it matters — Harrow watchers would care because positive discomfort-reduction data for IHEEZO could support the product's clinical profile in the ophthalmology space.

Harrow: The Q2 Turnaround Is Enough For A Cautious Buy

Seeking Alpha · 13 Aug 2026positive

Seeking Alpha upgraded Harrow from Hold to a cautious Buy following Q2 executional improvements and better visibility on operating leverage, citing improved VEVYE revenue and record IHEEZO demand.

Why it matters — The upgrade reflects growing confidence in Harrow's operational turnaround and revenue growth from its key products.

Harrow, Inc. (HROW) Q2 2026 Earnings Call Transcript

Seeking Alpha · 11 Aug 2026neutral

Seeking Alpha published the transcript of Harrow, Inc.'s Q2 2026 earnings call. The item is a plain transcript with no accompanying analysis or commentary.

Why it matters — Harrow watchers use earnings-call transcripts to review management's own discussion of quarterly results and outlook directly.

FAQ

Frequently asked questions about HROW stock

What is the HROW stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Harrow, Inc. have a median 12-month price target of $60, with estimates ranging from $45 to $88. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HROW stock a buy right now?

Of the 9 analysts covering Harrow, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Harrow, Inc. 45 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HROW?

As at 19 Sept 2026, Harrow, Inc. ranks 45 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (93 of 100).

Will HROW stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +76.9% from the last close, and Ticker Nerd's factor model ranks Harrow, Inc. 45 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HROW stock forecast for 2030?

No analyst covering Harrow, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HROW are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $45 to $88 over the next 12 months.

How has HROW stock performed over the past year?

Harrow, Inc. returned -23.5% over the 12 months to 21 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Harrow, Inc. do?

Harrow Inc. is an eyecare pharmaceutical company that develops, manufactures, and commercializes ophthalmic products for the U.S.

What is the latest news on HROW?

The most recent item we track (GlobeNewsWire, 1 Sept 2026): "Harrow to Participate in Three Investor Conferences in September". Harrow announced that its management will participate in three investor conferences in September in New York, NY, including the 2026 Cantor Global Healthcare Conference, scheduled for September 9, 2026, featuring a fireside chat and one-on-one investor meetings.

Company

About Harrow, Inc.

Harrow Inc. is an eyecare pharmaceutical company that develops, manufactures, and commercializes ophthalmic products for the U.S. market. Its portfolio includes prescription and non-prescription therapies used by eye care professionals to manage conditions affecting the front and back of the eye, such as dry eye disease, glaucoma, cataracts, retinal disorders, allergies, and infections. Harrow operates through branded pharmaceuticals and ImprimisRx, its ophthalmology-focused compounding business, giving it a broad commercial footprint across eye care settings. The company’s products are used in physician offices, clinics, and surgical environments, supporting routine treatment as well as specialized ophthalmic care. Headquartered in Nashville, Tennessee, Harrow focuses on accessible eye care solutions and a product mix that spans branded, compounded, and other ophthalmic formulations.

CEO Mr. Mark L. Baum J.D. · 373 employees · United States · https://www.harrow.com